Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Shingles vaccine safe and effective for HIV patients, study finds

NCT ID NCT05898464

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the shingles vaccine works and how safe it is for people living with HIV. Researchers compared the immune response based on participants' CD4+ T-cell counts and age. The goal was to provide evidence to help guide vaccination recommendations for this group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

71 people

The number who actually took part.

Started

Jun 2023

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (for HIV #1, HIV #2) : * 19 years old or older, HIV-1 infected person who have voluntarily agreed to participate in the study. * Have been taking antiviral medications stably for at least one month at the time of screening. * Have a CD4+ T-cell count measured before enrollment. * Do not have AIDS-defining diseases (excluding oral thrush) or acute/uncontrolled opportunistic infection at the time of enrollment. * Do not have uncontrolled chronic medical conditions other than HIV infection. Inclusion Criteria (for non-HIV) : * 50 years old or older who have voluntarily agreed to participate in the study. * Do not have uncontrolled chronic medical conditions Exclusion Criteria: * Have received any type of zoster vaccine within 1 year. * Have been diagnosed with chickenpox or shingles within 12 months. * Have a history of severe allergy to any of the components of Shingrix vaccine. * Have a acute medical condition at the time of screening. * Unable to be evaluated for adverse events via telephone contact after vaccination. * Pregnant (including those planning to become pregnant) or lactating women. * Those who have received chemotherapy or radiotherapy within 6 months prior to the first vaccine dose. * Chronic administration of immunosuppressive or other immune-modifying drugs within 6 months prior to ther first vaccine dose. * Administration of immunoglobulins, and/or any blood products within 3 months preceding the first dose of study vaccine * Have a medical condition that makes receiving an intramuscular injection medically contraindicated. * Have a disease or condition that may affect the immunogenicity or safety of the vaccine. * Receiving any other vaccine within 14 days prior to and 14 days after receiving the study vaccine. * Participate in a clinical trial that involves other investigational product or device during the course of the study. * Any other person who, in the opinion of the investigator, is unsuitable for immune response assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Medical Center

    Seoul, 04564, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.